Beta Pharma, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 20, 2027The maintenance fee for Indolinone protein kinase inhibitors (US 9,163,010) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Substituted 2-anilinopyrimidine derivatives as EGFR modulators (US 10,590,111) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,163,010 | Indolinone protein kinase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,878,994 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,239,864 | 2-H-INDAZOLE Derivatives as Cyclin-Dependent Kinase (CDK) Inhibitors and Therapeutic Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 10,590,111 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators In force · From the USPTO record | In force | From the USPTO record | |
| US 11,414,401 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators In force · From the USPTO record | In force | From the USPTO record | |
| US 11,052,086 | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers In force · From the USPTO record | In force | From the USPTO record | |
| US 10,844,045 | Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,180,478 | Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,352,341 | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,187,707 | Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 13: 3 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 4 no status recorded